News Articles

Solasia and Nippon Kayaku Announce License Agreement in Japan for New Drug Candidate DARINAPARSIN (SP-02) TOKYO -Thursday 28 October 2021

(BUSINESS WIRE)-- Solasia Pharma K.K. (TOKYO: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) and Nippon Kayaku Co., Ltd. (TOKYO: 4272, Headquarters: Tokyo, Japan, President: Atsuhiro Wakumoto) today jointly announced the conclusion of a license...

Solasia Announces Submission of New Drug Application for Anti-cancer Drug DARINAPARSIN for Peripheral T-Cell Lymphoma in... -Wednesday 30 June 2021

NDA filed in Japan ahead of anywhere else in the world New anti-cancer drug with a novel mechanism of action Darinaparsin is designated Orphan Drug in the US and EU as a treatment of peripheral T-cell lymphoma (PTCL)   (BUSINESS WIRE)-- Solasia Pharma K.K. (TSE: 4597,...

Solasia Announces Positive Results of DARINAPARSIN in Pivotal Phase 2 Study for Peripheral T-Cell Lymphoma -Monday 15 June 2020

- The primary endpoint (antitumor effect) was achieved - No new safety concerns were identified in the safety analysis - This study was conducted as the final registration trial for the indication of relapsed or refractory PTCL. Solasia begins preparing for the NDA Filing (BUSINESS...

Solasia Announces License and Capital Alliance for SP-04 (PledOx®) with Maruho -Thursday 12 December 2019

(BUSINESS WIRE)-- Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) announced today that it has entered into an exclusive license agreement with Maruho Co., Ltd. (Headquarters: Osaka, Japan, President & CEO: Koichi Takagi,...

Solasia Announces Patient Registration Reached Target Number of Cases for Darinaparsin Phase 2 Pivotal Study for T-Cell... -Tuesday 17 September 2019

(BUSINESS WIRE)-- Solasia Pharma K.K. (TSE:4597, Headquarters: Tokyo, President & CEO: Yoshihiro Arai, hereinafter “Solasia”), a specialty pharmaceutical company based in Asia, today announced that patient registration reached the target number of cases for the darinaparsin Phase 2...